<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340085</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Label-Free Quantitative Proteomics Analysis of COVID-19 Vaccines by Nano LC-HRMS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1055</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091055</ELocationID><Abstract><AbstractText>A nanoliter liquid chromatography-high resolution mass spectrometry-based method was developed for quantitative proteomics analysis of COVID-19 vaccines. It can be used for simultaneous qualitative and quantitative analysis of target proteins and host cell proteins (HCPs) in vaccine samples. This approach can directly provide protein information at the molecular level. Based on this, the proteomes of 15 batches of COVID-19 inactivated vaccine samples from two companies and 12 batches of COVID-19 recombinant protein vaccine samples from one company were successfully analyzed, which provided a significant amount of valuable information. Samples produced in different batches or by different companies can be systematically contrasted in this way, offering powerful supplements for existing quality standards. This strategy paves the way for profiling proteomics in complex samples and provides a novel perspective on the quality evaluation of bio-macromolecular drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hengzhi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wendong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z211100002121007</GrantID><Agency>Beijing Municipal Government</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">host cell proteins</Keyword><Keyword MajorTopicYN="N">nano LC-HRMS</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340085</ArticleId><ArticleId IdType="pmc">PMC11436057</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091055</ArticleId><ArticleId IdType="pii">vaccines12091055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z., et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81. doi: 10.1126/science.abc1932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1932</ArticleId><ArticleId IdType="pmc">PMC7202686</ArticleId><ArticleId IdType="pubmed">32376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty M., Buchy P., Standaert B., Giaquinto C., Prado-Cohrs D. Vaccine impact: Benefits for human health. Vaccine. 2016;34:6707–6714. doi: 10.1016/j.vaccine.2016.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.025</ArticleId><ArticleId IdType="pubmed">27773475</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Sastre A., Mena I. Novel vaccine strategies against emerging viruses. Curr. Opin. Virol. 2013;3:210–216. doi: 10.1016/j.coviro.2013.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.02.001</ArticleId><ArticleId IdType="pmc">PMC3644304</ArticleId><ArticleId IdType="pubmed">23477832</ArticleId></ArticleIdList></Reference><Reference><Citation>Savina K., Sreekumar R., Soonu V.K., Variyar E.J. Various vaccine platforms in the field of COVID-19. Beni-Suef Univ. J. Basic Appl. Sci. 2022;11:35. doi: 10.1186/s43088-022-00215-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-022-00215-1</ArticleId><ArticleId IdType="pmc">PMC8899459</ArticleId><ArticleId IdType="pubmed">35284578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotez P.J., Bottazzi M.E. Whole inactivated virus and protein-based COVID-19 vaccines. Annu. Rev. Med. 2022;73:55–64. doi: 10.1146/annurev-med-042420-113212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042420-113212</ArticleId><ArticleId IdType="pubmed">34637324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Hunter A.K., Mozier N.M. Host cell proteins in biologics development: Identification, quantitation and risk assessment. Biotechnol. Bioeng. 2009;103:446–458. doi: 10.1002/bit.22304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.22304</ArticleId><ArticleId IdType="pubmed">19388135</ArticleId></ArticleIdList></Reference><Reference><Citation>Toinon A., Fontaine C., Thion L., Gajewska B., Carpick B., Nougarede N., Uhlrich S. Host cell protein testing strategy for hepatitis B antigen in hexavalent vaccine-Towards a general testing strategy for recombinant vaccines. Biologicals. 2018;54:1–7. doi: 10.1016/j.biologicals.2018.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2018.05.006</ArticleId><ArticleId IdType="pubmed">29861269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tscheliessnig A.L., Konrath J., Bates R., Jungbauer A. Host cell protein analysis in therapeutic protein bioprocessing–methods and applications. Biotechnol. J. 2013;8:655–670. doi: 10.1002/biot.201200018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.201200018</ArticleId><ArticleId IdType="pubmed">23436780</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauchessec M., Hesse A.M., Kraut A., Berard Y., Herment L., Fortin T., Bruley C., Ferro M., Manin C. An innovative standard for LC-MS-based HCP profiling and accurate quantity assessment: Application to batch consistency in viral vaccine samples. Proteomics. 2021;21:2000152. doi: 10.1002/pmic.202000152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.202000152</ArticleId><ArticleId IdType="pubmed">33459490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui L., Lu H., Lee Y.H. Challenges and emergent solutions for LC-MS/MS based untargeted metabolomics in diseases. Mass Spectrom. Rev. 2018;37:772–792. doi: 10.1002/mas.21562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mas.21562</ArticleId><ArticleId IdType="pubmed">29486047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinaixa M., Schymanski E.L., Neumann S., Navarro M., Salek R.M., Yanes O. Mass spectral databases for LC/MS- and GC/MS-based metabolomics: State of the field and future prospects. TrAC Trends Anal. Chem. 2016;78:23–35. doi: 10.1016/j.trac.2015.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trac.2015.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucci P., Saurina J., Núñez O. Trends in LC-MS and LC-HRMS analysis and characterization of polyphenols in food. TrAC Trends Anal. Chem. 2017;88:1–24. doi: 10.1016/j.trac.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trac.2016.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauh M. LC–MS/MS for protein and peptide quantification in clinical chemistry. J. Chromatogr. B. 2012;883:59–67. doi: 10.1016/j.jchromb.2011.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2011.09.030</ArticleId><ArticleId IdType="pubmed">22000960</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhan L., Dai L., Yao X., Qin Y., Zhu Z., Zhang M., Tong W., Wang G. Evaluation of the reliability of MS1-based approach to profile naturally occurring peptides with clinical relevance in urine samples. Rapid Commun. Mass Spectrom. 2022:e9369. doi: 10.1002/rcm.9369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcm.9369</ArticleId><ArticleId IdType="pubmed">35906701</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Tan M., Zhu J., Tian Y., Liu H., Luo F., Wang J., Huang Y., Zhang Y., Yang Y., et al. Proteomic analysis of human milk reveals nutritional and immune benefits in the colostrum from mothers with COVID-19. Nutrients. 2022;14:2513. doi: 10.3390/nu14122513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14122513</ArticleId><ArticleId IdType="pmc">PMC9227629</ArticleId><ArticleId IdType="pubmed">35745243</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallien S., Duriez E., Demeure K., Domon B. Selectivity of LC-MS/MS analysis: Implication for proteomics experiments. J. Proteomics. 2013;81:148–158. doi: 10.1016/j.jprot.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2012.11.005</ArticleId><ArticleId IdType="pubmed">23159602</ArticleId></ArticleIdList></Reference><Reference><Citation>Díaz-Dinamarca D.A., Salazar M.L., Castillo B.N., Manubens A., Vasquez A.E., Salazar F., Becker M.I. Protein-based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: Current knowledge, challenges, and future opportunities. Pharmaceutics. 2022;14:1671. doi: 10.3390/pharmaceutics14081671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081671</ArticleId><ArticleId IdType="pmc">PMC9414397</ArticleId><ArticleId IdType="pubmed">36015297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y.-Y., Wang R.-R., Zhang D.-W., Chen S.-H., Tan Y.-Y., Zhang W.-T., Han M.-F., Fei G.-H. Differential characteristics of patients for hospitalized severe COVID-19 infected by the omicron variants and wild type of SARS-CoV-2 in China. J. Inflamm. Res. 2023;16:3063–3078. doi: 10.2147/JIR.S420721.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S420721</ArticleId><ArticleId IdType="pmc">PMC10368135</ArticleId><ArticleId IdType="pubmed">37497065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>